On October 13, WUXI XDC fell 4.24% in regular trading, trading at HK$80.65, with turnover of HK$31.78 million. The decline came amid broad weakness in the life sciences tools and services sector, with peers also trading lower.

Within the life sciences tools and services sector where WUXI XDC belongs, Genscript Bio down 10.54%, Insilico down 5.66%, XtalPi down 4.50%, WUXI BIO down 2.94%, and WUXI APPTEC down 1.73%. Goldman Sachs previously assigned a Buy rating with a target price of HK$97.90, highlighting the upcoming first FDA inspection of the Wuxi production facility, but near-term sector sentiment is dominating trading.

WUXI XDC is an investment holding company primarily engaged in providing comprehensive contract research, development, and manufacturing organization services for antibody-drug conjugates and other bioconjugates.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)